NASDAQ: AMLX - Amylyx Pharmaceuticals

Yield per half year: +1.96%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Amylyx Pharmaceuticals

Extended chart Simple chart
Financial Markets by TradingView

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. -  основана в 2014 году, фармацевтическая компания на клинической стадии,  которая разрабатывает новые терапевтические средства для лечения бокового амиотрофического склероза (БАС) и других нейродегенеративных заболеваний. Их главный продукт AMX0035 — это двойной ингибитор апоптоза UPR-Bax, состоящий из фенилбутирата натрия, или PB, и TURSO. Они стремятся к коммерциализации продукта  AMX0035, который, является первым кандидатом в лекарство, демонстрирующим как функциональные преимущества, так и выживаемость в крупномасштабных клинических испытаниях.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2022-01-07
ISIN US03237H1014
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт https://amylyx.com
Цена ао 3.78
Change price per day: +4.58% (3.49)
Change price per week: +6.41% (3.43)
Change price per month: -6.65% (3.91)
Change price per 3 month: +4.29% (3.5)
Change price per half year: +1.96% (3.58)
Change price per year: +73.81% (2.1)
Change price per 3 year: -52.29% (7.65)
Change price per year to date: -14.72% (4.28)
All parameters

Underestimation

Title Value Grade
P/S 2.95 6
P/BV 1.56 8
P/E 20.23 7
EV/EBITDA -0.6261 0
Total: 6.25

Efficiency

Title Value Grade
ROA, % -84.87 0
ROE, % -100.88 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.7 7
Total: 2.63

Debt

Title Value Grade
Debt/EBITDA -0.0068 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 13341.69 10
Yield Ebitda, % 627.6 10
Yield EPS, % 376.14 10
Total: 10
More

Institutions Volume Share, %
Vanguard Group Inc 5 7.86
Blackrock Inc. 4 6.58
Goldman Sachs Group Inc 3 4.33
Millennium Management LLC 2 3.63
Morgan Stanley 2 3.04
State Street Corporation 2 3.03
Franklin Resources, Inc. 2 2.73
Boxer Capital, LLC 2 2.21
Two Sigma Investments, LP 1 2.11
Citadel Advisors Llc 1 1.96

ETFShare, %Profitability for 1 year, %Dividends, %
Principal Healthcare Innovators ETF 0.01937 618.5 0.8416
Future Tech ETF 0.01937 426.34 0.8416
0.02522.420.84



Head Job title Payment Year of birth
Ms. Gina M. Mazzariello Chief Legal Officer & General Counsel 794.83k 1971 (54 years)
Ms. Shauna Horvath Head of Global Marketing N/A
Mr. Tom Holmes Chief Technical Operations Officer N/A
Mr. Chris Aiello Head of Canada & GM N/A
Mr. Joshua B. Cohen Co-Founder, Co-CEO & Director 1M 1992 (33 years)
Mr. Justin B. Klee Co-Founder, Co-CEO & Director 1M 1991 (34 years)
Mr. James M. Frates M.B.A. Chief Financial Officer 695.12k 1967 (58 years)
Lindsey Allen Head of Investor Relations & Communications N/A
Ms. Linda A. Arsenault Chief Human Resources Officer N/A
Dr. Camille L. Bedrosian M.D. Chief Medical Officer 1953 (72 years)

Address: United States, Cambridge. MA, 43 Thorndike Street - open in Google maps, open in Yandex maps
Website: https://amylyx.com